RecruitingNot Applicable

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Italy100 participantsStarted 2024-03-26

Plain-language summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); * At least 4 monthly migraine days; * Good compliance to study procedures; * Availability of headache diary at least of the preceding months before enrollment. Exclusion Criteria: * Subjects with contraindications for use of gepants; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding. * Changes in preventive treatments in the month before the first administration of rimegepant

What they're measuring

Changes in migraine frequency after three months of treatment

Timeframe: Baseline (T0) - 3 months of treatment with rimegepant (T3)

Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant

Timeframe: Baseline (T0) - 3 months of treatment with rimegepant (T3)

Trial details

NCT IDNCT06409832

SponsorUniversity of Florence

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-01-01

Contact for this trial

Luigi F Iannone, MD

+393896969606 luigifrancesco.iannone@unimore.it

View on ClinicalTrials.gov More Migraine trials